非肌层浸润性膀胱癌的监测:识别收益递减点
基于斯德哥尔摩县1995至1996年确诊的非肌层浸润性膀胱癌患者26年队列随访数据,结合微模拟模型模拟10000例患者的第一、二次复发与进展。低、中、高危患者15年首次复发率分别为56.6%、62.8%、48.7%,肌层浸润进展率分别为2.2%、4.3%、14.3%。数据提示5年无复发的低、中、高危患者或可转为侵入性更小的监测。
要点
- 386例患者中37.5%为美国泌尿外科协会高危,中位复发时间300天。
- 模拟15年首次复发率低危56.6%、中危62.8%、高危48.7%。
- 9年后未见首次复发,5年后复发率低但值得注意。
核心结论
- 数据提示5年无复发的低、中、高危患者或可转为侵入性更小的监测。
研究设计与样本
- 纳入1995至1996年斯德哥尔摩县确诊的非肌层浸润性膀胱癌患者,收集临床、病理及纵向随访数据。
- 采用逻辑回归、Kaplan-Meier曲线和Cox比例风险模型生成假设,构建微模拟模型模拟10000例患者的第一、二次复发与进展。
- 共纳入386例患者,67.4%为男性,>50%为TaLG,37.5%为美国泌尿外科协会高危,3例数据缺失,队列随访已进行26年。
主要发现
- 中位复发时间300天。
- 模拟首次复发:低危患者15年随访复发率56.6%,肌层浸润进展率2.2%;中危患者复发率62.8%,肌层浸润进展率4.3%;高危患者15年复发率48.7%,肌层浸润进展率14.3%。
- 模拟第二次复发:低、中、高危患者复发率分别为70.7%、75.7%、84.7%。
- 9年后未见患者发生首次复发,5年后复发率低但值得注意。
临床怎么用
- 作者认为,5年无复发的低、中、高危患者或可转为侵入性更小的监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize first and second recurrence patterns using 26years of cohort-level follow-up and microsimulation modeling. METHODS: Patients diagnosed with nonmuscle-invasive bladder cancer in Stockholm County between 1995 and 1996 were included. Clinical, pathological, and longitudinal follow-up data were gathered. Logistic regressions, Kaplan Meier curves, and Cox proportional hazards models were run to generate assumptions for a microsimulation model, simulating first and second recurrence and progression for 10,000 patients. RESULTS: Three hundred eighty-six patients were included: 67.4% were male; >50% were TaLG; and 37.5% were American Urological Association high-risk. Median time to recurrence was 300days. Three patients had missing data. Cohort follow-up has been carried out for 26years. For simulated first-recurrences, low-risk patients recurred at 56.6% over 15years of follow-up, with 2.2% muscle-invasive (MI) progression; intermediate-risk patients recurred at 62.8%, with 4.3% MI progression; high-risk patients recurred at 48.7% over 15years, with MI progression at 14.3%. For second recurrences, 70.7%, 75.7%, and 84.7% of low, medium, and high-risk patients recurred. No patients were seen to have first recurrences after 9years, with low, but notable, rates beyond 5years. CONCLUSION: These data suggest that low-, intermediate-, and high-risk patients without recurrence at 5years may be potentially transitioned to less invasive monitoring.
引用
- Ranti D, Dey L, Bieber C, et al. Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns. Urology. 2023. PMID: 37604253. doi:10.1016/j.urology.2023.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。